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Introduction: The host anti-tumour inflammatory response is a strong prognostic indicator, and tumour in-
filtrating lymphocytes (TILs) are believed to have a complimentary role alongside TNM assessment in dictating
future management. However, there is wide disagreement regarding the most efficacious and cost-effective
method of assessment.
Methods: A comprehensive literature search was performed of EMBASE, MedLine and PubMed as well as an
assessment of references to identify all relevant studies relating to the assessment of the peri-tumoural in-
flammatory response or TILs and prognosis in colorectal cancer (CRC). A meta-analysis was performed of 67
studies meeting the REMARK criteria using RevMan software.
Results: Intratumoural assessment of both CD3 and CD8 in CRC were significant for disease-free survival (DFS)
(combined HRs 0.46; 95%CI: 0.39–0.54 and 0.54; 95%CI: 0.45–0.65), as well as overall survival (OS) and
disease-specific survival (DSS). The same was true for assessment of CD3 and CD8 at the invasive margin (DFS:
combined HRs 0.45; 95%CI: 0.33–0.61 and 0.51; 95%CI: 0.41–0.62). However, similar fixed effects summaries
were also observed for H&E-based methods, like Klintrup-Makinen grade (DFS: HR 0.62; 95%CI: 0.43–0.88).
Furthermore, inflammatory assessments were independent of MSI status.
Conclusion: The evidence suggests that it is the density of a co-ordinated local inflammatory infiltrate that
confers survival benefit, rather than any individual immune cell subtype. Furthermore, the location of individual
cells within the tumour microenvironment does not appear to influence survival. The authors advocate a
standardised assessment of the local inflammatory response, but caution against emphasizing the importance of
any individual immune cell subtype.
Introduction
Colorectal cancer (CRC) represents a significant health burden with
1.8 million deaths worldwide in 2018 related to the disease [1]. It has
increasingly been recognised over recent decades that whilst TNM
staging has significant prognostic value in CRC, it does not take account
of the interaction between host and tumour [2]. It has been repeatedly
demonstrated that the local host inflammatory response to the tumour
has significant positive prognostic value, hence the recent addition of
immune checkpoint inhibitors to the therapeutic repertoire for CRC [3].
However, an assessment of the local inflammatory response remains
only an optional item on the CRC reporting dataset [4].
There remains a drive towards inclusion in the TNM classification
system of an assessment of the local immune response [5,6]. However,
one of the barriers to implementing routine clinical assessment of the
anti-tumour immune response is the heterogeneity in the methodology
employed in identifying and quantifying this reaction. It has not, for
example, been comprehensively shown whether a haematoxylin and
eosin (H&E)-based assessment or immunohistochemical (IHC)
assessment of individual inflammatory cells is superior in terms of
prognostic benefit, since a recent review of tumour-infiltrating
lymphocytes in solid tumours by the International Immuno-Oncology
Biomarkers Working Group concluded that, in colorectal cancer, further
work was required to define the “most appropriate balance between
simplicity and depth of information” [7].
Assessment of TILs has already been established in the pathology
reporting dataset for malignant melanoma, although there is ongoing
discussion regarding the method of assessment [8]. Indeed, there has
been a move to standardise assessment of TILs in many solid tumours
and this would be beneficial to enable identification of those that may
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ben-efit from immunotherapy.
Several H&E methods have been employed in addition to many in-
dividual inflammatory cells from both the innate and adaptive immune
system. A further area of contention relates to which tumour com-
partment should be assessed for these individual immune cell subtypes.
Menon and colleagues described a basement-membrane or “BM-like
structure” that appeared to prevent infiltration of immune cells into the
tumour, when staining for antilaminin on IHC [9]. There are others who
advocate that those tumours that have a strong intratumoural infiltra-
tion, so called “immune hot” tumours, are associated with better
prognosis [10]. Therefore, it is important to establish whether there is
any evidence of superiority or not of assessing intratumoural vs the
invasive margin in terms of prognostication.
Furthermore, the use of tissue microarrays (TMAs) has been em-
ployed by many to allow rapid throughput of many tumour specimens
simultaneously in addition to reducing inter-sample variations in
staining. However, TMAs may limit the location-specific assessment of
prognosis. Similarly, differences in quantification of immune cell den-
sity ranging from semiquantitative assessment and manual counts to
digital pathology-based assessments and automated cell counting has
led to difficulty in standardising a method for clinical implementation
[11–13].
Microsatellite instability (MSI) must also be accounted for when
considering tumour infiltrating lymphocytes. Hereditary MSI, in addi-
tion to sporadic cases of MSI, account for around 15% of all colorectal
cancers [14]. When testing was first introduced for MSI, it was purely
based on genetic assessment, which was expensive. High density of
tumour infiltrating lymphocytes was one of the markers used in the
screening process to select patients for testing [14], since MSI cancers
were known to be immunogenic [15–17] – a feature of MSI tumours
that has subsequently been attributed to high neo-antigen load [18].
With the advent of more economical immunohistochemical assessment
for loss of DNA-mismatch repair proteins and BRAF, it has become more
economical to assess for the presence of MSI in all colorectal tumours to
guide adjuvant therapy [19]. Immunotherapies are currently only li-
censed for use in MSI-high colorectal cancer in view of the poor re-
sponse of microsatellite stable (MSS) tumours during clinical trial [3].
However, the effects of immunotherapies remain untested in selected
individuals with a prominent immune response in MSS CRC. It remains
to be seen whether these individuals would derive benefit from ad-
juvant immunotherapy in this context.
This review seeks to present the available evidence for survival
outcomes based on assessment of the peritumoural immune response in
colorectal cancer and to outline a possible strategy for incorporating
assessment of the immune microenvironment in colorectal cancer into
clinical practice.
Methods
Search strategy
The aim of the literature search was to identify all primary studies
that assessed the anti-tumour inflammatory response in colorectal
cancer and its relation to prognosis among patients with resected col-
orectal cancer. PubMed, Ovid MEDLINE and EMBASE databases were
searched on the 1st May 2019 using the following criteria:
1. “Colon cancer” OR “Rectal Cancer” OR “Colorectal cancer” (in
Abstract) AND
2. “Survival” OR Prognos$ (in Abstract) AND
a. “Klintrup-Makinen” OR KM OR “Crohn’s-like reaction” OR CLR
OR “peritumo$ inflamm$” (in Abstract) OR
b. “Cytotoxic or CD8 or CD3 or CD4 or T-cell or Tcell or lymphocyte
or macrophage or CD68 or CD163 or “natural killer” or CD56 or
CD57 or CD45RO or FoxP3 or Treg or T-reg or CD20 or “tumo$
infiltrating lymphocytes” or TILs” (in Abstract) AND
c. Immunohistochemistry (in any field)
One reviewer (P.G.A) made an inspection of the titles and abstracts
of citations to identify relevant studies and obtain full texts. A further
search was made of the reference lists to identify studies not identified
in the original search. The search was limited to English language,
published from 1997 to present and studies in humans.
Methodologic and validity assessment
Study inclusion criteria were derived from published REMARK
guidelines [20]. Eligible studies were included if meeting criteria in
Table 1.
Data extraction
One author (P.G.A) performed a review of all eligible manuscripts.
Any contentious articles were discussed with the other authors (DCM
and JHP) and agreement was reached regarding articles for inclusion
and exclusion. The extracted study data included: year of publication;
stage of disease; time period of sample; specimen used for assessment
(whether biopsy, TMA or whole section); for TMA, number and size of
cores, if given; whether colon or rectal (if specified) or colorectal;
haematoxylin and eosin (H&E) staining or antibody used for IHC;
counting method; whether MSI was assessed and how this was handled
in statistical analysis; specific survival outcome. On the rare occasion
where hazard ratios were given without a 95% CI, the P-value was
utilised to give an estimation of the standard error. Only studies that
performed multivariate analysis were included. However, given the
high numbers of studies that combined multiple immune variables in
multivariate analysis, univariate hazard ratios were entered into meta-
analysis. An assessment of bias was made based on REMARK guidelines
criteria and the table is presented in supplementary data.
Statistical analysis
Studies were grouped according to whether they assessed rectal,
colon or colorectal cancer for any given variable. In addition, studies
were subgrouped by type of survival assessed: whether disease-free
survival, which was defined as time to disease recurrence and included
the terms “recurrence-free survival” and “progression-free survival”;
overall survival, which was defined as time to death from any cause; or
dis-ease-specific survival, which was defined as time to cancer-related
death and also included the term “cancer-specific survival”. The loca-
tion of inflammatory assessment performed was defined as Intra-
Tumoural (IT) or at the Invasive Margin (IM). For IT, studies were in-
cluded regardless of whether they performed an assessment within
cancer cell nests (or intra-epithelial (IE)) or in tumour stroma (ST) or
combined (IE + ST). Studies using an “immunoscore-type” method (i.e.
combining high scores from both IT and IM areas) for assessing a single
inflammatory cell subtype were included in the IT assessment only.
Studies with a sample size of less than 100 were excluded from meta-
analysis. For single studies of a particular inflammatory assessment, the
Table 1
Inclusion criteria of prognostic studies of anti-tumour inflammatory response.
1. Either prospective or retrospective design with a well-defined study population
2. Study of rectal, colon or colorectal cancer primary resections
3. Assessment on FFPE slides using a standardised H&E assessment or IHC staining for
a specified inflammatory cell population of interest
4. Clear description of the specimen used for assessment, antibodies used, tumour
compartment assessed and counting method.
5. Groupings of patients and data cutoffs.
6. Description of statistical analysis methods used.
7. For meta-analysis, only those papers reporting a proportional hazard model used,
including details of adjustment variables.
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HR and 95% CI for that study are reported. Where multiple studies
evaluated the same inflammatory assessment, a fixed effects summary
HR is given with 95% CI. Where the Hazard Ratio was greater than 1.0,
this indicated a worse survival for higher value of a given inflammatory
variable and vice versa. Confidence intervals crossing 1.0 were con-
sidered non-significant. Inter-study heterogeneity was also assessed and
presented as the I2 value. Publication bias was assessed by funnel plot.
Meta-analyses were performed using REVMAN systematic review and
meta-analysis software, version 5.3.
Results
Literature search and exclusion of studies
Literature search yielded a total of 1064 manuscripts for assessment
(Fig. 1). After exclusion of duplicates (n = 243 studies), non-human
studies (n = 74 studies), non-English language (n = 16 studies) and
conference abstracts (n = 273), titles and abstracts were reviewed for
458 studies. Full texts were obtained for the 152 relevant studies.
Following careful scrutiny of these, 12 studies were excluded due to
Literature search performed on 
5th April 2019
1064 manuscripts
Exclusions:
•243 duplicates
•74 non-human
•16 non-English language
•273 conference abstracts
458 titles and abstracts reviewed
Exclusions:
•306 did not meet inclusion criteria
152 relevant full texts reviewed
Exclusions (12):
•5 insufficient statistical analysis
•4 insufficient detail
•4 replicated results
140 studies included in 
systematic review
Exclusions from meta-analysis (60)
•45 studies did not report hazard ratios
•4 studies did not perform multivariate 
analysis
•9 studies only stage IV disease
•1 did not define the follow up period
•1 assessed a different tumour region
•13 had sample size <100
67 studies included in 
meta-analysis
Fig. 1. Flow diagram of literature search and included/excluded studies.
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insufficient statistical analysis, insufficient detail, or replication of re-
sults from a previous work. This left 140 studies with sufficiently de-
tailed methodology and patient cohort assessing inflammatory in-
filtration in colon, rectal and colorectal cancer (Table 2 and
supplementary data). When performing meta-analysis, however, a fur-
ther 60 studies were excluded, for reasons presented in flow diagram
(Fig. 1). Finally, the decision was made to exclude 13 studies with small
sample size (n < 100) due to the low event rate and reliability of
results. This left a final total of 67 studies for meta-analysis, summary of
included studies in Supplementary Table S1. Assessment of bias is
shown in Supplementary Table S2. All studies included in meta-analysis
were of good quality with low risk of bias and only one study scoring
moderate risk.
Of those studies included in the meta-analysis, 35 performed as-
sessment on whole sections, 29 on TMAs, and the remaining 3 on a
combination of TMA and whole sections (n = 2) or TMA and biopsy
(n = 1). TMA sizes varied and included cores ranging from 0.6 mm to
3 mm, with core size not provided for 4 studies. Automated cell
counting was utilized in 21 studies, while the remaining 46 used
manual assessment methods. Only 27 studies documented that blinding
was performed to patient outcome. Sample size varied from 103 up to
2681 patients. The majority (n = 51) contained less than 500 patients.
The median study size was 285, with an interquartile range of 160–478.
Sixty-nine percent of papers assessed the presence of MSI, however 26%
of those did not include it in the multivariate analysis. There were over
45 adjustment variables used in multivariate analysis, although the
most common were age (n= 45), sex (n= 37), grade (n= 35), N-stage
(n = 29), TNM (n = 29) , T-stage (n = 27), MSI (n = 24), tumour site
(n = 22), lympho-vascular/perineural invasion (n = 21), other in-
flammatory assessment (n = 21), adjuvant therapy (n = 12) and M-
stage (n = 8).
H&E assessment of inflammatory infiltrate
Since 1997, thirty-two studies were identified that assessed survival
in the context of an H&E-based assessment of the peritumoural
inflammatory infiltrate in colon, rectal or colorectal cancer: Jass/
Klintrup-Makinen, Crohn’s like reaction, tumour-infiltrating lympho-
cyte counts or a combination of these. Four studies had overlapping
cohorts [21–24], leaving twenty-eight independent studies with a total
of 11423 patients [9,25–51]. Two studies did not find a significant
survival difference for any H&E-based method [9,37], whereas the
other twenty-six studies found significantly prolonged survival for pa-
tients with higher local inflammatory infiltrate with a total number of
10887 patients [25–36,38–51].
Klintrup-Makinen and Jass
The most common method of assessment was the Klintrup-Makinen
grade (KM) or Jass scoring systems: two related, but separate systems
assessing the quantity of the overall local inflammatory infiltrate. The
Jass score was first reported in rectal cancer in 1986 and claimed to be
the first to show an independent association of the lymphocytic in-
filtrate with survival [52]. They described the lymphocytic infiltrate at
the invasive margin (IM) or “advancing front” of the tumour as pro-
nounced, moderate, little or none. Prominent inflammation at the IM
appeared as a “cap” or continuous layer, whereas moderate in-
flammation was more broken or interrupted with fewer lymphocytes,
while they combined “little” and “none” into one category. They found
this 3-point scale was able to stratify rectal cancer survival into 3 dis-
tinct bands. Klintrup and colleagues [22] developed a similar pheno-
typic assessment of the local inflammatory infiltrate at the IM in 2005,
with a 4 point scale, scoring a “cup-like” infiltrate as 3, band-like as 2,
interrupted band as 1 or minimal inflammation as 0. They further
added in the destruction of cancer cells in the top two scores and di-
chotomised their score with the upper and lower two categories being
combined into high vs low, respectively.
Eighteen studies assessed the inflammatory infiltrate using KM or
Jass scoring, although one of these had an overlapping cohort [22],
leaving seventeen independent studies and a total of 4904 patients: four
of these studies found no significant difference [9,21,34,37]; the re-
maining thirteen found significantly better survival for higher KM or
Table 2
Summary table of all papers reporting survival outcomes based on peritumoural inflammatory infiltrate and inflammatory cell subtypes.
Measurement of local inflammatory
response
Total number of
studiesa
Studies reporting significant positive
associationa (%)
Studies reporting significant
negative associationa
Studies reporting no survival
associationa
Inflammatory infiltrate on H&E
Klintrup-Makinen/Jass 18 14 (78) 4
CLR 14 13 (93) 1
TILs (H&E) 9 8 (89) 1
Combined assessment 2 2 (100) 0
Any H&E method 32 30 (94) 2
T-lymphocyte subsets
CD3 (generic T-cell) 34 24 (71) 10
CD8 (cytotoxic T-cell) 62 46 (74) 16
CD4 (helper T-cell) 15 6 (40) 9
CD45RO (memory T-cell) 15 12 (80) 3
FoxP3 (regulatory T-cell) 34 21b (62) 2b (6) 12
Combined T-cells 86 67b (78) 2b (2) 18
Immunoscore 14 13 (93) 1
B-lymphocytes (CD20) 6 5 (83) 1
Natural killer cells (CD56, CD57) 6 5 (93) 1
Macrophages (CD68, CD163, CD206)
CD68 17 10 (59) 1 (6) 6
CD163 7 2 (29) 3 (43) 2
CD206 1 0 1 (100) 0
Combined macrophages 22 12 (55) 5 (23) 5
Total 140 119c (85) 7c (5) 16
a Numbers in columns will not add up as many studies looked at more than one marker.
b One study both positive and negative.
c Two studies reported both positive and negative findings.
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Jass scores, with a total of 4046 patients [25,26,29–33,35,36,38–41]. In
terms of interobserver agreement, the original study by Jass quoted
interobserver agreement as 0.72 [52]. However, in these 19 studies,
interobserver agreement was only reported for KM by two groups with
kappa values ranging from 0.05 to 0.48 in one study [26] and 0.50 to
0.79 in another [22].
Nine independent studies assessed the presence of MSI: of which
two found peritumoural inflammation to be independent of MSI in
survival [26,36]; one only included MSI tumours and did not find
peritumoural inflammation to be associated with survival [21]; three
found MSI to have no association with survival [38,39,41]; and three
did not include MSI in survival analysis [9,33,35].
Only one study met inclusion criteria for meta-analysis for KM in
colon cancer finding it significant for OS and DSS (Table 3). Six studies
were included for KM in colorectal cancer (Table 4, Fig. 2): three
analysing DFS (HR 0.62, 95% CI: 0.43–0.88); two for OS (HR 0.43; 95%
CI: 0.26–0.71); and three for DSS (HR 0.40; 95% CI: 0.29–0.55). There
was no significant heterogeneity between studies for any survival type.
In addition, the funnel plot for KM shows no clear publication bias.
There were no studies in rectal cancer that met inclusion criteria for
meta-analysis.
Crohn’s-like reaction
The Crohn’s-like reaction (CLR), described by Graham and
Appelman in 1990 [53], which assesses the number of “discrete lym-
phoid aggregates”, with or without germinal centres, at the IM and
spread through the muscularis propria. The CLR is considered part of
the adaptive immune response against the cancer, with aggregates
consisting largely of B-cells, and to a lesser degree T-cells and antigen-
presenting cells [41]. The original method of assessing this response
scored more than 3 aggregates and at least 1 germinal centre as “in-
tense”, vs a “mild” reaction if 2 or fewer aggregates or none if absent
[53]. Various groups attempting to validate this method have combined
two of these categories into one, whether none and mild vs intense
[28,48], or none vs mild or intense [22]. Two adaptations to this have
been proposed and validated. The first was proposed by Ueno and
colleagues in 2013, scoring CLR on a size-based criteria: any aggregate
of> 1 mm in diameter was classed as “active” [50]. A further method
of scoring CLR was proposed by Vayrynen and colleagues in 2014,
which measures the “density” of reaction by dividing the total number
of aggregates by the length of the IM: any density of greater than 0.38
follicles/mm (calculated by ROC curve) is classed as high density [41].
Still others have measured a B-cell response on H&E by performing
manual counts of plasma cells at the IM [23] or within the tumour [45].
Fourteen studies reported CLR or plasma cell counts although three
of these had overlapping cohorts [21,22,24], leaving eleven in-
dependent studies comprising a total of 6595 patients, all of which
found a significantly better survival for high CLR
[23,26,28,36,41,43,45,46,48–50]. Seven independent studies (3803
patients) used the Graham-Appelman (G-A) method of assessment: four
of these (2337 patients) used a cut-off of greater that one (grouping
absent and mild together) [28,46,48,54], of which only one found that
CLR was not associated with survival and this was in a cohort of solely
MSI tumours [54]; while the other three (1466 patients) used a cut-off
of greater than zero (grouping mild and intense together) [22,26,36], of
which one found that CLR was not associated with survival [22]. An-
other paper adjusted the criteria for intense staining to greater than 5
lymphoid aggregates but there was only one tumour in this category,
therefore effectively this paper also combined mild and intense
Table 3
Meta-analysis results for papers meeting inclusion criteria for Colon cancer.
Impact of study methodology on heterogeneity testing (I2 test) and overall effect
Overall effect Heterogeneity
Location assessed Survival type No. of studies HR 95% CI I2 test (%) P-value First Author Surname/year
Klintrup-Makinen/Jass
OS 1 0.63 0.42–0.95 NA Hynes
DSS 1 0.48 0.31–0.75 NA Hynes
Crohn’s-like reaction
G-A OS 1 0.64 0.48–0.86 NA Hynes
DSS 1 0.60 0.42–0.85 NA Hynes
Tumour infiltrating lymphocytes (H&E)
DFS 1 0.37 0.15–0.90 NA Turner
OS 1 0.45 0.23–0.87 NA Turner
CD3
IT DFS 2 0.59 0.38–0.91 3 0.31 Guidoboni, Sinicrope
OS 3 0.49 0.33–0.71 0 0.83 Guidoboni, Miller, Sinicrope
DSS 1 0.35 0.14–0.88 NA Miller
IM OS 1 0.48 0.22–1.03 NA Miller
DSS 1 0.65 0.50–0.84 NA Miller
CD8
IT DFS 1 0.35 0.16–0.76 NA Guidoboni
OS 3 0.58 0.41–0.83 34 0.22 Guidoboni, Miller, Yoon
DSS 1 0.77 0.32–1.87 NA Miller
IM OS 1 0.84 0.41–1.71 NA Miller
DSS 1 0.77 0.32–1.87 NA Miller
FoxP3
IT DFS 1 1.23 0.72–2.13 NA Sinicrope
OS 2 0.91 0.59–1.40 86 0.008 Miller, Sinicrope
DSS 1 0.28 0.12–0.66 NA Miller
Immunoscore
DFS 1 0.63 0.52–0.75 NA Pages 18
OS 1 0.70 0.58–0.84 NA Pages 18
Bold studies: Right sided tumours only
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Table 4
Meta-analysis results for papers meeting inclusion criteria for Colorectal cancer.
Impact of study methodology on heterogeneity testing (I2 test) and overall effect
Overall effect Heterogeneity
Location assessed Survival type No. of
studies
HR 95% CI I2 test
(%)
P-value First Author Surname/year
Klintrup-Makinen/Jass
DFS 3 0.62 0.43–0.88 0 0.39 Climent, Klintrup, Menon
OS 2 0.43 0.26–0.71 0 0.45 Climent, Ogino
DSS 3 0.40 0.29–0.55 0 0.91 Ogino, Park 14, Vayrynen 14
Crohn’s-like reaction
G-A DFS 1 0.87 0.26–2.89 NA Lee 16
OS 4 0.68 0.60–0.78 53 0.09 Bae, Buckowitz, Ogino, Rozek
DSS 2 0.64 0.54–0.77 0 0.60 Ogino, Rozek
Ueno criteria DFS 2 0.49 0.37–0.64 0 0.98 Kim 15a, Ueno 15
DSS 1 0.40 0.20–0.80 NA Ueno 13
Vayrynen criteria DFS 1 0.50 0.28–0.89 NA Kim 15a
DSS 1 0.54 0.37–0.79 NA Vayrynen 2014
Any method DFS 3 0.51 0.39–0.66 0 0.84 Kim 15a, Ueno 15, Lee 16
OS 4 0.68 0.60–0.78 53 0.09 Bae, Buckowitz, Ogino, Rozek
DSS 4 0.61 0.52–0.71 0 0.50 Ogino, Rozek, Ueno 13, Vayrynen 14
Tumour infiltrating lymphocytes (H&E)
DFS 3 0.65 0.51–0.83 0 0.37 Climent, Lee 16, Ropponen
OS 4 0.73 0.64–0.84 0 0.73 Climent, Nielsen, Ogino, Rozek
DSS 3 0.66 0.55–0.78 0 0.95 Ogino, Ropponen, Rozek
Combined H&E inflammatory assessment
OS 1 0.50 0.31–0.81 NA Ogino
DSS 1 0.31 0.15–0.65 NA Ogino
CD3
IT DFS 6 0.46 0.39–0.54 56 0.04 Chen 16, Deschoolmeester, Erisken, Galon 06, Kim 18, Vayrynen 16
OS 8 0.57 0.50–0.64 73 <0.001 Berntsson 17, Chen 16, Deschoolmeester, Eriksen, Galon 06, Kim 18, Nosho, Vayrynen
16
DSS 6 0.59 0.50–0.70 0 0.82 Dahlin, Nosho, Richards 14, Simpson, Vayrynen 12, Vayrynen 16
IM DFS 3 0.45 0.33–0.61 0 0.69 Deschoolmeester, Galon 06, Vayrynen 16
OS 4 0.71 0.59–0.85 67 0.03 Deschoolmeester, Galon 06, Nosho, Vayrynen 16
DSS 6 0.58 0.48–0.69 10 0.35 Dahlin, Laghi, Nosho, Richards 14, Vayrynen 12, Vayrynen 16
CD8
IT DFS 8 0.46 0.39–0.54 48 0.06 Chen 16, Deschoolmeester, Eriksen, Kim 18, Mori, Prall, Tosolini, Vayrynen 16
OS 15 0.63 0.58–0.67 65 <0.001 Berntsson 17, Chen 16, Deschoolmeester, Erisken, Kasajima, Kim 18, Naito,
Nazemalhosseini-Majorad, Nosho, Oshikiri, Pages 09, Prizment, Salama, Vayrynen 16,
Zlobec 2008c
DSS 9 0.62 0.56–0.69 73 <0.001 Baker, Chiba, Ling, Nosho, Pages 09, Prall, Prizment, Richards 14, Vayrynen 16
IM DFS 4 0.50 0.40–0.62 0 0.81 Deschoolmeester, Kim 15b, Tosolini, Vayrynen 16
OS 4 0.62 0.51–0.75 58 0.05 Deschoolmeester, Kim 15b, Nosho, Vayrynen 16
DSS 5 0.53 0.45–0.63 53 0.05 Lugli, Matsutani, Nosho, Richards 14, Vayrynen 16
CD4
IT DFS 1 0.55 0.32–0.96 NA Chen 16
OS 2 0.64 0.42–0.97 0 0.72 Chen 16, Kasajima
DSS 1 0.64 0.41–0.99 NA Ling
CD45RO
IT DFS 3 0.52 0.40–0.69 83 0.003 Chen 16, Kim 15b, Pages 09
OS 5 0.68 0.61–0.75 78 0.001 Chen 16, Kim 15b, Nosho, Pages 09, Salama
DSS 3 0.53 0.44–0.64 83 0.002 Nosho, Pages 09, Richards 14
IM DFS 1 0.42 0.33–0.54 NA Kim 15b
OS 2 0.51 0.42–0.63 77 0.01 Kim 15b, Nosho
DSS 2 0.57 0.47–0.68 70 0.07 Nosho, Richards 14
FoxP3
IT DFS 2 0.52 0.36–0.77 27 0.24 Chen 16, Vayrynen 16
OS 4 0.72 0.65–0.80 77 0.004 Chen 16, Nosho, Salama, Vayrynen 16
DSS 3 0.47 0.37–0.61 0 0.40 Nosho, Richards 14, Vayrynen 16
IM DFS 1 0.42 0.19–0.93 NA Vayrynen 16
OS 2 0.47 0.35–0.63 0 0.81 Nosho, Vayrynen 16
DSS 3 0.57 0.46–0.70 62 0.07 Nosho, Richards 14, Vayrynen 16
Immunoscore
DFS 3 0.49 0.41–0.58 91 <0.001 Mlecnik, Pages 09, Wirta
OS 3 0.61 0.53–0.70 89 <0.001 Mlecnik, Pages 09, Wirta
DSS 5 0.47 0.39–0.55 86 <0.001 Mlecnik, Nearchou, Pages 09, Park 16, Wirta
CD20
IT DFS 1 0.62 0.40–0.96 NA Chen 16
OS 2 0.66 0.52–0.89 0 0.50 Berntsson 16, Chen 16
(continued on next page)
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Table 4 (continued)
Impact of study methodology on heterogeneity testing (I2 test) and overall effect
Overall effect Heterogeneity
Location assessed Survival type No. of
studies
HR 95% CI I2 test
(%)
P-value First Author Surname/year
CD56/57
IT DFS 2 0.47 0.28–0.78 71 0.06 Chen 16, Tachibana
OS 2 0.48 0.28–0.84 33 0.22 Chen 16, Tachibana
CD68
IT DFS 3 1.21 0.95–1.55 81 0.005 Chen 16, Kim 18, Vayrynen 16
OS 5 0.91 0.75–1.11 77 0.002 Chen 16, Gulubova, Kim 18, Koelzer 16, Vayrynen 16
DSS 2 0.58 0.38–0.89 0 0.56 Algars, Vayrynen 16
IM DFS 1 0.43 0.19–0.96 NA Vayrynen 16
OS 3 0.48 0.36–0.64 48 0.15 Gulubova, Li 18a, Vayrynen 16
DSS 1 0.40 0.20–0.81 NA Vayrynen 16
CD163/206
IM DFS 1 3.68 1.74–7.82 NA Shibutani 17
DSS 1 0.66 0.42–1.05 NA Edin
Bold studies: MSI high only studies
Fig. 2. Forest plot and funnel plot for KM/Jass classification in colorectal cancer according to DFS, OS and DSS.
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reactions and found CLR to be significant for survival [43]. The only
group to report different cut-offs for the G-A method in the same cohort
assessed only patients with MSI and found that a cut-off of greater than
0 (144 high vs 25 low) was significant [21], whereas a cut-off of greater
than 1 (48 high vs 164 low) was not [49]. This was probably because
the lower cut-off selected out those patients in this cohort who had MSI
but a poor local inflammatory response for worse survival. Three in-
dependent studies (2073 patients) used a digital pathology method of
assessing CLR: one using the size or Ueno method [50]; one using the
density or Vayrynen method [41]; one compared the original G-A
method with the Ueno and Vayrynen methods in a cohort of MSI-high
tumours [54]. All three studies found that Ueno and Vayrynen methods
were significant for survival. Interobserver agreement for the G-A
method was reported as around 0.50 [49,50] with a range of 0.29 to
0.92 [26,28]. The Ueno method had a reported agreement of 0.56 [49]
to 0.67 [50] and the Vayrynen method, 0.71–0.81 [41,49]. The only
paper to directly compare all three methods found the Vayrynen den-
sity-based method to be the most reproducible [49].
Eight independent groups assessed the presence of MSI: of which
four found CLR to be independent of MSI [26,36,46,49]; two found that
MSI was not independently significant for survival [41,48]; and two did
not include MSI in survival analysis [43,50].
Only one study met inclusion criteria for meta-analysis for CLR in
colon cancer using the G-A method and finding it significant for OS and
DSS (Table 3). Five studies were included for G-A method in colorectal
cancer (Table 4, Fig. 3A): only one assessed DFS finding it to be sig-
nificant for survival; four assessed OS (HR 0.68; 95% CI: 0.60–0.78);
and two DSS (HR 0.64; 95% CI: 0.54–0.77). There was no significant
heterogeneity for DSS, although for OS, there was moderate hetero-
geneity with an I2 of 53% (p = 0.09). Three studies met inclusion
criteria for meta-analysis for the Ueno method in colorectal cancer
(Table 4, Fig. 3B): two of these assessed DFS (HR 0.49; 95% CI:
0.37–0.64), with no significant heterogeneity and one assessed OS,
finding it to be significant for survival. Two studies were included for
the Vayrynen method (Table 4, Fig. 3C), both finding it significant for
survival: one for DFS and the other for DSS. The funnel plot for the G-A
method shows no evidence of publication bias, whereas those for Ueno
and Vayrynen criterion, there were too few studies to comment on
publication bias. There were no studies assessing CLR in rectal cancer.
TILs on H&E
TILs have been referred to by many groups when considering an H&
E based assessment. However, some are referring to an assessment at
the invasive margin similar to the KM grade [55]. Papers describing
TILs on H&E were considered when an assessment was made of at least
one IT compartment, whether IE, ST or combined IE + ST.
There were nine independent studies that assessed TILs in this way
in relation to survival in colon or colorectal cancer with a total of 5508
patients [27,33,36,42–47], of which eight studies showed a positive
association with survival, comprising 5343 patients [27,36,42–47],
while one showed no association [33]. There was no assessment of
interobserver variability reported in any of the studies. Six studies as-
sessed the presence of MSI: of which two found that TILs were in-
dependent of MSI in survival [36,46]; one found that MSI was not
significant for survival [27]; while three did not include MSI in survival
analysis [33,43,44]. Four studies assessed the density of TILs semi-
quantitatively [27,36,42,43], while five counted cells and assigned a
cut-off [33,44–47].
Only one study met inclusion criteria for meta-analysis for TILs on H
&E sections in colon cancer, finding it significant for DFS and OS
(Table 3, Fig. 4). For colorectal cancer, six studies were included for
TILs on H&E sections (Table 4): three assessed DFS (HR 0.65; 95% CI:
0.51–0.83); four assessed OS (HR 0.73; 95% CI: 0.64–0.84); and three
assessed DSS (HR 0.66; 95% CI: 0.55–0.78). There was no significant
heterogeneity between the studies for any survival outcome. Funnel
plot shows no significant publication bias. There were no studies as-
sessing TILs on H&E in rectal cancer.
Combined inflammatory assessment on H&E
Ogino and colleagues developed a combined scoring system in 843
patients assessing KM, CLR, ST TILs and IE TILs. A semiquantitative
score was assigned for each element of peritumoural inflammation.
Each element of the score was found to be individually significant for
survival apart from IE TILs. All four elements were given equal
weighting and combined into a total score. An arbitrary cut-off was
subsequently set to separate the cohort into 3 categories. The combined
inflammatory score was found to be independently significant for OS
and CSS and was independent of MSI [36]. Another group performed
the same assessment, comparing the score’s efficacy in a Caucasian
population comprising 159 patients and an Afro-American population
comprising 52 patients. The score was not significant in the Caucasian
population but was significant in the Afro-American population and
independent of MSI [51].
One study had to be excluded from meta-analysis due to lack of
follow up data [51]. Hazard ratios for the combined H&E assessment in
colorectal cancer (Table 4) were significant for both OS and DSS. There
were no studies in rectal or colon cancer utilising the combined H&E
assessment.
MSI and H&E assessment of peritumoural inflammation
Sixteen original studies comparing H&E assessment of peritumoural
inflammation and survival also took MSI into consideration
[9,26,27,33,35,36,38,39,41,43,44,46,48–51]. However, of those six-
teen: six studies did not enter MSI into multivariate analysis
[9,33,35,43,44,50]; five found that MSI was not significant for survival
[27,38,39,41,48]; but the remaining 5 studies found that peritumoural
inflammation was independent of MSI for prognostic significance (3820
patients) [26,36,46,49,51]. One of these studies was exclusively in 212
MSI colorectal cancers and found CLR to be significant for survival even
in this group [49].
T-lymphocyte subsets
The adaptive immune response includes the actions of a variety of
immune cells with varying functions, both pro-inflammatory and im-
munosuppressive, which includes T-cells with a range of phenotypes:
from CD4 helper T-cells, to CD8 cytotoxic T-cells, to FoxP3 regulatory
T-cells and CD45RO memory T-cells.
Eighty-six studies were identified that assessed rectal, colon or
colorectal cancer survival according to T-cell marker assessment using
immunohistochemistry. However, many of these studied overlapping
cohorts or assessed more than one marker [21,30,54,56–75]. In terms
of independent cohorts studied in relation to different T-cell markers,
there was a total of 63 studies, encompassing 14700 patients
[9,13,37,39,76–134]. Of the total studies, 67 found a significant posi-
tive effect for T-cell infiltration in and around the tumour, but only 47
of these studied independent cohorts, with a total number of 13014
patients [9,13,37,39,76–80,82,83,85,86,89,90,92–95,97–101,103–105,
107–109,112,114,116–119,121–125,127–130,132,133]. Two studies
found a negative survival impact regarding FoxP3 expression [57,130],
of which one found both negative and positive effects [130]. Eighteen
studies did not find any significant survival difference according to T-
cell infiltration, although only 14 of these assessed independent cohorts
[84,87,88,91,96,102,106,110,111,113,115,120,126,134]. Many stu-
dies compared more than one T-cell marker and included multiple in-
flammatory markers or MSI [70,81,83,92,95,132] in multivariate ana-
lysis [30,61,78,83,85,90,92,98,104,117–119,127,130], with the result
that although each marker was highly significant on univariate ana-
lysis, the survival advantage was not independent of other markers of
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inflammation. This suggests that a functional host immune response
results in a better outcome, regardless of which markers are assessed.
CD3 (generic T-cell marker)
CD3, a generic T-cell marker expressed by the majority of T-cells
[135], was assessed in thirty-four studies in relation to survival in rectal,
colon or colorectal cancer, although two studies had overlapping cohorts
[59,61]. There were, therefore, thirty-two independent cohorts comprising
a total of 7947 patients [30,58,60,63,68,76–99,102,118,127]. CD3 was
found to have a significant positive association with survival in twenty-
four of these, of which twenty-three were independent and comprised
5292 patients [30,58,60,63,76–81,83,85,86,89,90,92–95,97–99,127]. Ten
studies found no significant association of CD3 with survival
[59,68,82,84,87,88,91,96,102,118].
In rectal cancer, there were two papers comprising 229 patients
assessing CD3 [76,102], both of which assessed the intratumoural
compartments in pre-treatment biopsies, but only one was significant
for survival (136 patients) [76]. The latter used a manual method of
assessment [76], the other used an electronic counting method [102].
Fig. 3. Forest plots and funnel plots for CLR DFS, OS and DSS in colorectal cancer, as measured by: (A) Graham-Appelman method; (B) Ueno method; and (C)
Vayrynen method.
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Neither study assessed the presence of MSI. Both studies used a median
cut-off with equal group sizes. Neither met criteria for inclusion in
meta-analysis.
In colon cancer, there were 6 studies comprising 591 patients that
assessed the relation of CD3 infiltration with survival
[58,61,77–79,127]. All found a significant association with survival.
Five of these (502 patients) assessed the intratumoural compartments
[58,61,77,79,127]. Two assessed the invasive margin in addition to
other areas of the slide [78,79]. Three studies compared different tu-
mour regions in the same cohort and of these: one found that the IE CD3
was significant for survival, whereas ST CD3 was not [58]; one found
both IM CD3 and total slide CD3 were significant for survival [78]; and
one found that intratumoural CD3 was significant where IM CD3 was
not [79]. Three studies assessed the presence of MSI: one of which
found no association of MSI with survival and it was therefore not in-
cluded in multivariate analysis [79]; whereas 2 were independent of
MSI [58,77]. Four papers used an electronic method of assessment
[77–79,127], whereas 2 used a manual assessment [58,61]. Five of the
studies used various different arbitrary data cut-offs [58,61,77,78,127],
whereas one study used a “data-driven” cut-off[79].
Three studies met inclusion criteria for meta-analysis for IT CD3 in
colon cancer (Table 3, Fig. 5A): two assessed DFS (HR 0.59; 95% CI:
0.38–0.91), with no significant heterogeneity; three assessed OS (HR
0.49; 95% CI: 0.33–0.71), with no significant heterogeneity; and one
study assessed DSS finding a significant survival benefit. There were too
few studies to interpret the funnel plot for IT CD3. Only one study met
inclusion criteria for IM CD3 in colon cancer (Table 3, Fig. 5B). There
was a trend towards a significant survival benefit for OS, although this
was not significant and there was no significant survival benefit for
DSS.
In colorectal cancer, there were 26 studies comprising 7230 patients
assessing the relation of CD3 infiltration with survival
[30,59,60,63,68,80–99,118]. Seventeen of these, with 4633 patients,
found a positive association of CD3 with survival [30,60,63,80,81,83,
85,86,89,90,92–95,97–99], compared with 9 studies (with 2597 pa-
tients) finding no significant survival difference [59,68,82,84,87,88,
96,118]. Nineteen studies (5414 patients) assessed CD3 in the in-
tratumoural compartments [30,60,68,81–94,96,98] and of these 12
Fig. 4. Forest plot and funnel plot for TILs on H&E in colorectal cancer according to DFS, OS and DSS.
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studies (3579 patients) found a significant association with survival
[30,60,81,83,85,86,89,90,92–94,98]. Nine studies (1641 patients) as-
sessed CD3 and the invasive margin [30,80,81,83,84,87,89,91,98], of
which 4 studies (775 patients) were significant for survival
[30,80,83,98]. Six studies (1668 patients) assessed CD3 on the whole
slide [59,63,95,97,99,118] of which four (906 patients) were sig-
nificant for survival [63,95,97,99]. Seven studies significant for sur-
vival assessed more than one tumour region and of these: three found
that IE CD3 and not ST CD3 was significant for survival [81,83,94],
whereas three found that both IE CD3 and ST CD3 were significant for
survival [85,89,98]; two studies found that intratumoural assessment of
CD3 was significant whereas assessment at the invasive margin was not
[81,89], while three found that assessment of both intratumoural and
invasive margin CD3 was significant for survival [30,83,98]. Nine
studies assessed the presence of MSI: of these two studies found CD3 to
be independent of MSI [80,83]; two studies found no association of MSI
with survival and therefore it was not included in multivariate analysis
[86,88]; a further two studies did not include MSI in survival analysis
[85,94]; and in 3 studies CD3 was not independent of MSI on multi-
variate analysis [81,92,95]. Fifteen studies used an electronic method
of assessment [59,60,63,80,82,83,85,86,90–93,97,99,118] of which 11
found CD3 to be significant for survival
Fig. 5. Forest plots and funnel plots for CD3 according to DFS, OS and DSS: (A) IT in colon cancer; (B) IM in colon cancer; (C) IT in colorectal cancer; (D) IM in
colorectal cancer.
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[60,63,80,83,85,86,90,92,93,97,99]. Twelve studies used a manual
assessment method [30,68,81,84,87–89,94–98], of which 7 found CD3
to be associated with survival [30,81,89,94,95,97,98]. The only study
to directly compare electronic and manual methods of CD3 as-sessment
in colorectal cancer found both to be comparable and significant for
survival [97]. Thirteen studies used various different arbitrary data cut-
offs [68,81,84–86,88–90,94–96,98,118], whereas 9 studies used data-
driven cut-offs [60,63,80,82,83,92,93,97,99]. In four studies, the cut-
off method employed was unclear [30,59,87,91].
Twelve studies met inclusion criteria for meta-analysis for IT CD3 in
colorectal cancer (Table 4, Fig. 5C): six assessed DFS (HR 0.46; 95% CI:
0.39–0.54), with moderate heterogeneity between these results (I2 56%;
p = 0.04); eight assessed OS (HR 0.57; 95% CI: 0.50–0.64), with sub-
stantial heterogeneity (I2 73%; p < 0.001); and six assessed DSS (HR
0.59; 95% CI: 0.50–0.70), with no significant heterogeneity. The funnel
plot showed no evidence of publication bias. Eight studies were in-
cluded for IM CD3 (Table 4, Fig. 5D): three assessed DFS (HR 0.45; 95%
CI: 0.33–0.61), with no significant heterogeneity; four assessed OS (HR
0.71; 95% CI: 0.59–0.85), with substantial heterogeneity (I2 67%;
p = 0.03); and six assessed DSS (HR 0.58; 95% CI: 0.48–0.69), with no
significant heterogeneity. Funnel plot did not reveal any publication
bias.
CD8 (cytotoxic T-cells)
CD8 is a cytotoxic T-cell marker, whose role is to recognise a foreign
antigen presented by an antigen presenting cell and to bind cells ex-
pressing that antigen, inducing cell lysis and recruiting other immune
cells with the release of cytokines [136]. CD8 was assessed in 62 studies
in relation to survival in rectal, colon or colorectal cancer, although
there were twelve studies whose cohorts overlapped
[21,54,56,59,60,64,65,67–69,75,137], leaving 50 studies assessing
CD8 in independent cohorts comprising a total of 12868 patients
[9,13,30,37,39,70,71,76–79,81–86,88,89,91–93,98,100–125,134].
CD8 was found to be significant for survival in 46 studies, but only 37 of
these were in independent cohorts [9,13,30,37,39,70,71,76–78,
81–83,85,86,92,93,98,100,101,103–105,107–109,112,114,116–119,
121–125] comprising 11085 patients. CD8 was not significantly asso-
ciated with survival in 16 studies, of which 13 were independent
[79,84,88,89,91,102,106,110,111,113,115,120,134].
In rectal cancer, there were eleven independent studies assessing
CD8 and survival comprising 1749 patients [64,69,76,100–106,137].
Nine of these were significant for survival (1463 patients)
[64,69,76,100,101,103–105,137]. Seven studies assessed CD8 in in-
tratumoural compartments on pre-treatment biopsies (949 patients)
[69,76,100–104]. Of these, three found a significant association of CD8
in pre-treatment biopsies with survival (497 patients) [69,76,103].
While six studies (1269 patients) assessed CD8 in the intratumoural
compartment of resected specimens [100,101,103,104,106,137], of
which four studies (804 patients) were significantly associated with
improved survival [100,101,104,137]. Two studies assessed the com-
bined invasive margin and intratumoural compartments for CD8 in-
filtration (162 patients), both of which were significant for survival
[64,105]. Four studies assessed CD8 infiltration in biopsies taken prior
to neo-adjuvant therapy, in addition to post-resection specimens: of
these, three studies (346 patients) found that CD8 levels in the resected
specimen were significantly associated with survival while those in the
biopsies were not [100,101,104]; whereas in 1 study (285 patients)
CD8 in the biopsy and not the resected specimen was associated with
survival [103]. Only one study in full resection specimens compared
more than one tumour compartment, finding ST CD8 to be significantly
associated with survival, where IE CD8 was not [101]. Three studies
used an electronic method of assessment [64,101,102], of which 2
studies found CD8 to be significant for survival [64,101]. Eight studies
used a manual assessment method [69,76,100,103–106,137], of which
7 found CD8 to be significant for survival [69,76,100,103–105,137].
Three studies assessed the presence of MSI: of which 1 did not find MSI
to be independently significant for survival [106]; whereas the other 2
did not include MSI in the survival analysis [69,137]. Nine studies used
an arbitrary cut-off [69,76,100–106], of which 7 found CD8 to be sig-
nificant for survival [69,76,100,101,103–105]. Two studies used a
data-driven cut-off, both of which were significant for survival
[64,137].
Three studies met inclusion criteria for meta-analysis for IT CD8 in
rectal cancer (Table 5, Fig. 6A): one assessed DFS and OS, finding only
DFS to be significant for survival; and two assessed DSS (HR 0.52; 95%
CI: 0.39–0.69), with substantial heterogeneity (I2 73%; p = 0.05).
Funnel plot could not be interpreted due since there were too few
studies. No studies met inclusion criteria for meta-analysis of IM CD8 in
rectal cancer.
In colon cancer, there were six independent studies (811 patients)
assessing CD8 and survival: of which four (650 patients) found a sig-
nificant impact on survival [67,77,78,107], whereas 2 did not [79,134],
although one of these was in stage IV disease [134]. All the studies
assessing CD8 in colon cancer assessed the intratumoural compartment.
The only study assessing both IE CD8 and ST CD8 separately found both
to be significant for survival [107]. Two studies (193 patients) assessed
CD8 at the invasive margin [78,79], of which only one (89 patients)
was significant for survival [78]. Only one study (89 patients) assessed
CD8 on the whole slide, finding it to be significant for survival [78].
This study was also the only study with significant results comparing
intratumoural and invasive margin CD8, finding both to be significant
for survival [78]. Three studies used an electronic method of assessment
[77–79], of which two found CD8 to be significant for survival [77,78].
Three studies used a manual method of assessment [67,107,134], of
which 2 found CD8 to be significant for survival [67,107]. Four studies
Table 5
Meta-analysis results for papers meeting inclusion criteria for Rectal cancer.
Impact of study methodology on heterogeneity testing (I2 test) and overall effect
Overall effect Heterogeneity
Location assessed Survival type No. of studies HR 95% CI I2 test (%) P-value First Author Surname/year
CD8
IT DFS 1 0.38 0.14–0.99 NA Chen 19
OS 1 0.44 0.13–1.53 NA Chen 19
DSS 2 0.52 0.39–0.69 73 0.05 Rosenbaum, Zlobec 08a
FoxP3
IT DFS 1 0.72 0.56–0.93 NA Reimers
OS 1 0.73 0.56–0.95 NA Reimers
CD56/57
IT OS 1 0.23 0.08–0.66 NA Alderdice
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assessed the presence of MSI: of which 1 found IE CD8 to be in-
dependent of MSI [77]; one found ST CD8, but not IE CD8 to be in-
dependent of MSI [107]; one found that MSI was not significant for
survival [79]; and one excluded all MSI patients from survival analysis
[67]. Four studies used an arbitrary data cut-off for analysis
[77,78,107,134], of which 3 were significant for survival [77,78,107].
Two studies used a data-driven cut-off [67,79], of which one was sig-
nificant [67].
Four studies met inclusion criteria for meta-analysis for IT CD8 in
colon cancer (Table 3, Fig. 6C): one assessed and was significant for
DFS; three assessed OS (HR 0.58; 95% CI: 0.41–0.83), with moderate
heterogeneity (I2 34%; p = 0.22); and one assessed DSS finding no
significant difference in survival. Funnel plot could not be assessed for
publication bias. Two studies were included for IM CD8: one assessed
DFS finding borderline significance; the other assessed OS and DSS
finding no significant survival difference for either.
In colorectal cancer, there were 44 papers assessing CD8, 38 of
which (11274 patients) assessed independent cohorts
[9,13,30,37,39,59,70,71,81–86,88,89,91–93,98,108–125], of which 26
independent studies (9903 patients) found CD8 to be significant for
survival [9,13,30,37,39,70,71,81–83,85,86,92,93,98,108,109,112,114,
116–119,121–125]. Thirty-four independent studies (10168 patients)
assessed intratumoural CD8 [9,13,30,37,39,70,71,81–86,88,89,
91–93,98,108–117,119–122,125], of which 25 (8736 patients) were
significant for survival [13,30,37,39,70,71,81–83,85,86,92,93,98,108,
109,112,114,116,117,121,122,125]. Of the nine studies that directly
compared intratumoural CD8 assessment: three studies (625 patients)
found IE significant where ST was not [75,81,121]; two studies (460
patients) found ST significant where IE was not [83,125]; three studies
(1294 patients) found both IE and ST to be significant [71,85,98]; and
one (291 patients) study compared IE assessment with combined as-
sessment of IE and ST and found IE alone to be significant [37]. There
were 17 independent studies (4027 patients) that assessed CD8 at the
invasive margin [9,30,54,71,75,81,83,84,89,91,98,109,111,120,
123–125], of which eight (2491 patients) found IM CD8 to be sig-
nificant for survival [9,54,71,98,109,123–125]. Ten studies (2271 pa-
tients) compared CD8 at the IM and in the intratumoural compartment:
of which only one (96 patients) found IM CD8 to be significant for
survival where intratumoural measures were not [9]; four studies (691
patients) found intratumoural CD8 significant where IM CD8 was not
[30,75,81,83]; five studies (1484 patients) found both intratumoural
and IM CD8 to be significant for survival [54,71,98,109,125]. Four
Fig. 6. Forest plots and funnel plots for CD8 according to DFS, OS and DSS: (A) IT in rectal cancer; (B) IT in colon cancer; (C) IM in colon cancer.
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independent studies compared CD8 on the whole slide (combined IM
and intratumoural): of which three (1335 patients) were significant for
survival [71,109,118]; and one was not significant, but this study was
small with only 35 patients [59]. Fifteen independent studies (5475
patients) used an electronic method of assessment
[13,59,82,83,85,86,91–93,109,111,117–120], of which 11 (4949 pa-
tients) found CD8 to be significant for survival
[13,82,83,85,86,92,93,109,117–119]. Twenty-two independent studies
(5534 patients) used a manual method of assessment
[9,30,37,39,70,71,81,84,88,89,98,108,110,112–116,121–123,125], of
which 16 (4689 patients) found CD8 to be significant for survival
[9,30,37,39,70,71,81,98,108,112,114,116,121–123,125]. Eighteen in-
dependent studies assessed the presence of MSI: of which 4 found CD8
to be independent of MSI [71,108,121,125]; five found MSI to be not
significant for survival [39,86,88,113,117]; three found that CD8 was
not independent of MSI on multivariate analysis [81,83,92]; and six did
not include MSI in multivariate analysis [9,13,85,112,114,124].
Twenty-five studies (6853 patients) used an arbitrary data
cut-off [9,13,37,39,71,81,84–86,88,89,98,108,110–113,115,117–121,
123,125], of which 17 (5936 patients) found CD8 to be significant for
survival [9,13,37,39,71,81,85,86,98,108,112,117–119,121,123,125].
Seven studies used a data-driven cut-off, all of which found CD8 to be
significant for survival [82,83,92,93,109,114,124]. The cut-off was
unclear for 5 studies [30,59,91,116,122].
Twenty-two studies met inclusion criteria for meta-analysis for IT
CD8 in colorectal cancer (Table 4, Fig. 7A): eight assessed DFS (HR
0.46; 95% CI: 0.39–0.54), with moderate heterogeneity between these
results (I2 48%; p = 0.06); fifteen assessed OS (HR 0.63; 95% CI:
0.58–0.67), with substantial heterogeneity (I2 65%; p < 0.001); and
nine assessed DSS (HR 0.62; 95% CI: 0.56–0.69), with substantial het-
erogeneity (I2 73%; p < 0.001). The funnel plot revealed no significant
publication bias, although one study in particular is seen as an outlier
for DFS, OS and DSS [109].
Eight studies were included for IM CD8 (Table 4, Fig. 7B): four as-
sessed DFS (HR 0.50; 95% CI: 0.40–0.62), with no significant hetero-
geneity; four assessed OS (HR 0.62; 95% CI: 0.51–0.75), with sub-
stantial heterogeneity (I2 58%; p = 0.05); and five assessed DSS (HR
0.53; 95% CI: 0.45–0.63), with substantial heterogeneity (I2 53%;
p = 0.05). The funnel plot shows no significant publication bias. There
is one small left-sided outlier skewing results and heterogeneity for DSS,
although curiously only for one of the two populations in the same
study [125]. Exclusion of this outlying population resulted in no sig-
nificant heterogeneity for DSS, data not shown.
CD4 (predominantly helper T-cells)
CD4 is a surface marker predominantly expressed by helper T-cells,
although it is expressed to a lesser degree by other immune cells and
therefore is not entirely helper T-cell specific [138]. CD4 T-cells play a
considerable role in anti-cancer immunity with both cytotoxic cap-
abilities and roles in recruitment and priming both cytotoxic T-cells and
recruiting B-cells to the tumour microenvironment [139]. There were
Fig. 7. Forest plots and funnel plots for CD8 according to DFS, OS and DSS: (A) IT in colorectal cancer; (B) IM in colorectal cancer.
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fifteen studies on CD4 and rectal or colorectal cancer survival, but the
cohort in one overlapped with another [113], leaving fourteen in-
dependent studies comprising 2726 patients
[9,30,37,56,59,60,71,73,82,91,93,111,125,126]. One of these (62 pa-
tients) assessed survival in rectal cancer but did not meet inclusion
criteria for meta-analysis. They assessed pre-treatment biopsies but did
not find IT CD4 to be significant for survival [56].
The remaining thirteen independent studies (2664 patients) as-
sessed CD4 in colorectal cancer: of which six studies (1471 patients)
found CD4 to be significantly associated with better survival
[37,60,71,73,82,93]. Whereas the 7 remaining studies (1193 patients)
found no association between CD4 and survival
[9,30,59,91,111,125,126]. Eleven studies assessed intratumoural CD4
[9,30,37,60,71,73,82,91,93,111,125], of which six found it to be sig-
nificant for survival [37,60,71,73,82,93]. None of the 5 studies asses-
sing CD4 at the invasive margin, nor the 2 studies assessing CD4 on the
whole slide found any significant association with survival
[9,30,59,91,111,125,126]. There were no studies with significant
findings that compared CD4 in different tumour regions. Six studies
used an electronic method of assessment [59,60,82,91,93,111], of
which 3 found CD4 to be significant for survival [60,82,93]. Seven
studies used a manual method of CD4 assessment
[9,30,37,71,73,125,126], of which 3 found it to be significant for
survival [37,71,73]. Four studies assessed the presence of MSI: of which
2 found CD4 to be independent of MSI for survival [71,125]; one did
not find MSI to be significant for survival [113]; and one did not include
MSI in multivariate analysis [9]. Seven studies used an arbitrary data
cut-off [9,37,71,73,111,113,125], of which 3 found CD4 to be sig-
nificant for survival [37,71,73]. Three studies used a data-driven cut-
off, all of which were significant for survival [60,82,93]. The data cut-
off was unclear for 4 studies [30,59,91,126].
Three studies met inclusion criteria for meta-analysis for IT CD4 in
colorectal cancer (Table 4, Fig. 8): one assessed DFS finding a sig-
nificant survival benefit; two assessed OS (HR 0.64; 95% CI: 0.42–0.97),
with no significant heterogeneity; one assessed DSS finding a significant
survival benefit. There were too few papers to give meaningful results
from funnel plot analysis. No studies reporting IM CD4 were included in
meta-analysis. There were no studies identified addressing CD4 in colon
cancer.
CD45RO (effector memory T-cells)
CD45RO is a surface marker expressed by effector memory T-cells
and has largely been studied in this context. However, it can also be
expressed by B-cells and to a lesser degree by other immune cells and
therefore is not entirely effector memory T-cell specific [140–142]. The
Fig. 8. Forest plot and funnel plot for IT CD4 according to DFS, OS and DSS in colorectal cancer.
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role of effector memory T-cells is to enact a swift response to a re-
cognised foreign antigen [143]. There were fifteen studies assessing
CD45RO and survival in rectal, colon or colorectal cancer, one of which
had an overlapping cohort [61], leaving 14 independent studies com-
prising 4235 patients [54,60,69,84,93,98,109,111,117–119,122,
127,131]. Twelve studies found CD45RO to be associated with better
survival, but only eleven (3992 patients) of these were independent
[54,60,69,98,109,117–119,122,127,131].
In rectal cancer, there were two studies (263 patients) assessing
CD45RO, both finding it to be significantly associated with survival:
one of which performed a manual assessment of CD45RO in pre-treat-
ment biopsies [69], the other an electronic assessment in post-resection
specimens [131]. Neither study compared CD45RO in more than one
tumour region. One assessed the presence of MSI but did not include
this in multivariate analysis [69]. Both studies used an arbitrary data
cut-off. Neither study met inclusion for meta-analysis in rectal cancer.
In colon cancer, there were two studies (166 patients) assessing
intratumoural CD45RO, both finding it to be significantly associated
with survival: one of which used a manual method [61], while the other
used an electronic counting method [127]. Neither study assessed the
invasive margin, nor the presence of MSI. Both studies used an arbitrary
data cut-off. Neither met inclusion criteria for meta-analysis of CD45RO
in colon cancer.
In colorectal cancer, there were 11 studies (3885 patients) assessing
CD45RO and survival [54,60,84,93,98,109,111,117–119,122], of
which 8 studies (3642 patients) found a significant association with
survival [54,60,98,109,117–119,122]. In those not primarily assessing
stage IV disease, comprising 3590 patients, 7 out of 8 studies reported
survival advantage for those with high CD45RO
[54,60,98,109,111,117,118,122], with only 1 small study (27 patients)
reporting no significance [111]. Ten studies assessed intratumoural
CD45RO [54,60,84,93,98,109,111,117,119,122], of which seven found
it to be associated with survival [54,60,98,109,117,119,122]. The only
study comparing CD45RO in more than one intratumoural compart-
ment found both IE and ST CD45RO to be significantly associated with
survival [98]. Five studies assessed CD45RO at the invasive margin
[54,84,98,109,119], of which 4 found it to be significant for survival
[54,98,109,119]. Of the 4 studies that compared assessment at the in-
vasive margin compared with intratumoural assessment, all found that
both areas were associated with better survival [54,98,109,119]. Two
studies performed a combined assessment of the full slide (invasive
margin and intratumoural) and both found CD45RO to be significantly
associated with survival [109,118]. Eight studies used an electronic
method of assessment [54,60,93,109,111,117–119], of which 6 found
CD45RO to be significant for survival [54,60,109,117–119]. Of the 3
studies using a manual assessment method: two found CD45RO to be
significant for survival [98,122], whereas one did not [84]. Two studies
assessed the presence of MSI, but neither included it in multivariate
analysis [54,117]. Seven studies used an arbitrary data cut-off
[54,84,98,111,117–119], of which 5 found CD45RO to be significantly
associated with survival [54,98,117–119]. Three studies used a data-
driven cut-off [60,93,109] and 2 of these found CD45RO to be asso-
ciated with survival [60,109]. Data cut-off was unclear in one study
[122].
Six studies met inclusion criteria for meta-analysis for IT CD45RO in
colorectal cancer (Table 4, Fig. 9B): three assessed DFS (HR 0.52; 95%
CI: 0.40–0.69), with substantial heterogeneity between these results (I2
83%; p = 0.003); five assessed OS (HR 0.53; 95% CI: 0.61–0.75), with
substantial heterogeneity (I2 78%; p = 0.001); and three assessed DSS
(HR 0.53; 95% CI: 0.44–0.64), with substantial heterogeneity (I2 83%;
p = 0.002). As with CD8, the funnel plot revealed no significant pub-
lication bias, although one study in particular is seen as an outlier for
DFS, OS and DSS [109], skewing results to the left and removal of this
study from meta-analysis results in a large fall in the heterogeneity to
0%, 51% and 70% for DFS, OS and DSS, respectively (data not shown).
Three studies were included for IM CD45RO (Table 4, Fig. 9C): one
assessed DFS finding survival benefit; two assessed OS (HR 0.51; 95%
CI: 0.42–0.63), with substantial heterogeneity (I2 77%; p = 0.01); and
two assessed DSS (HR 0.57; 95% CI: 0.47–0.68), with substantial het-
erogeneity (I2 70%; p = 0.07). Funnel plot contained too few studies to
give meaningful data regarding publication bias, although the plot was
narrow indicating larger studies with similar results.
Fig. 9. Forest plots and funnel plots for CD45RO according to DFS, OS and DSS: (A) IT in colorectal cancer; (B) IM in colorectal cancer.
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FoxP3 (regulatory T-cells)
FoxP3 is commonly expressed by regulatory T-cells. A large body of
research has been performed on regulatory T-cells in a variety of can-
cers as well as non-neoplastic research. Due to the fact that their
function is to regulate the immune system by suppressing T-cell ac-
tivity, thereby preventing overactivity and autoimmunity [144], their
presence in and around colorectal cancer may be expected to be a poor
prognostic indicator as some have hypothesised [110]. Some have gone
as far as to say that they may be pro-tumour [110,145]. Thirty-four
studies were identified that assessed rectal, colon or colorectal cancer
prognosis related to FoxP3 expression in TILs, but there were three
overlapping cohorts [58,68,102], leaving 31 independent studies (7991
patients) [54,57,59,60,71,74,79,82–84,90,92,98,100,101,107,110,112,
115,117–120,126–130,132–134]. Twenty-one studies found FoxP3 to
be associated with better survival, but only twenty (6774 patients) of
these were independent [54,60,71,79,83,90,92,98,101,107,117–119,
127–130,132–134], compared with 2 studies (218 patients) finding
FoxP3 to have a detrimental impact on survival [57,130], one of which
had both positive and negative findings [130]. Twelve studies found no
impact of TILs FoxP3 expression on survival [58,59,74,82,84,100,
102,110,112,115,120,126].
In rectal cancer, there were four independent studies (840 patients)
assessing FoxP3: of which two (631 patients) found a positive asso-
ciation with survival [101,128]; one (128 patients) found a negative
association with survival [57]; and one found no association [100].
Three studies assessed FoxP3 in pre-treatment biopsies: of which only
one (153 patients) found it to have a significant positive association
with survival [101]; while the other two found no association
[100,102]. Four studies assessed the intratumoural compartment of
post-resection specimens: of which one study found a significant posi-
tive association with survival [128]; one found a significant negative
Fig. 10. Forest plots and funnel plots for FoxP3 according to DFS, OS and DSS: (A) IT in rectal cancer; (B) IT in colon cancer; (C) IT in colorectal cancer; (D) IM in
colorectal cancer.
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association [57]; and two found no significant association [100,101].
One study assessed FoxP3 in both pre-treatment biopsies and post-re-
section specimens, finding its presence in the biopsy to be significant for
better survival, whereas there was no survival significance of FoxP3 in
the resected specimen [101]. Of the two studies that assessed the same
cohort: one assessed FoxP3 in pre-treatment biopsies, finding no sig-
nificant difference to survival [102], whereas in the resected specimen,
there was a significant negative association of the presence of FoxP3
with survival [57]. No groups assessed the invasive margin or the whole
tumour slide for FoxP3 in rectal cancer. Two independent studies used
an electronic method of assessment and a data-driven cut-off, of which
one (128 patients) found a negative impact of FoxP3 infiltration in the
resected tumour on survival [57], whereas one (153 patients) found a
positive impact of FoxP3 in the pre-treatment biopsy on survival [101].
Two studies used a manual method of assessment and arbitrary cut-off,
of which one (81 patients) found no significant impact on survival in
pre-treatment biopsy or resected specimen [100], whereas one (478
patients) found a significant positive impact of FoxP3 on the resected
specimen [128]. No studies assessed the presence of MSI.
Only one study met inclusion criteria for meta-analysis of IT FoxP3
in rectal cancer (Table 5, Fig. 10A): assessing DFS and OS, with sig-
nificant positive survival association for both.
In colon cancer, there were five independent studies (540 patients)
assessing FoxP3, all of which found a positive association with survival
[79,107,127,129,134]. Four of these assessed the intratumoural com-
partments [79,107,127,134] and two assessed the invasive margin
[79,129]. The only study (104 patients) assessing both intratumoural
compartments and the invasive margin found that IT FoxP3 was sig-
nificant for better survival, whereas IM FoxP3 was not significant [79].
However, the other study of IM FoxP3 (136 patients) found that this
was significant for better survival [129]. None of the studies assessed
FoxP3 in the whole slide in colon cancer. Three studies used an elec-
tronic method of assessment [79,127,134], whereas two used a manual
assessment method [107,129]. Three studies assessed the presence of
MSI: of which one found the presence of FoxP3 to be independent of
MSI [107]; one found that MSI was not significant for survival [79]; and
one found that FoxP3 was not independent of MSI [129]. Three studies
used an arbitrary data cut-off [107,127,134], while two used a data-
driven cut-off [79,129].
Two studies met inclusion criteria for meta-analysis of IT FoxP3 in
colon cancer (Table 3, Fig. 10B): one assessed DFS finding no survival
association; two assessed OS (HR 0.91; 95% CI: 0.59–1.40), with sub-
stantial heterogeneity (I2 86%; p = 0.008); and one assessed DSS,
finding a significant positive survival association. The funnel plot was
wide and one reason for this is that some of the results tended towards
poorer survival and some towards better survival. No comment can be
made regarding publication bias since the number of studies was too
few.
In colorectal cancer, twenty-two independent studies (6611 pa-
tients) assessed the association [54,59,60,71,74,82–84,90,92,98,
110,112,115,117–120,126,130,132,133] of FoxP3: of which thirteen
(5603 patients) found it to be significant for survival [54,60,71,83,
90,92,98,117–119,130,132,133]. Nineteen independent studies (5220
patients) assessed intratumoural FoxP3 [54,60,71,74,82–84,90,92,
98,110,112,115,117,119,120,130,132,133], of which eleven studies
(4898 patients) were significantly associated with survival
[60,71,83,90,92,98,117,119,130,132,133]. One of these papers found
both negative and positive influence on survival depending on whether
FoxP3 T-cells were found in the intraepithelial compartment or com-
bined intraepithelial and stromal compartments, respectively [130].
There was only one other study with significant results that assessed
more than one intratumoural compartment for FoxP3, finding that both
IE and ST FoxP3 were significant for better survival [98]. Six in-
dependent studies (1597 patients) assessed FoxP3 at the invasive
margin [54,71,83,84,98,120], with a positive survival association in
four studies comprising 1281 patients [54,71,83,98]. Of the three
studies with significant findings that assessed both intratumoural FoxP3
and at the invasive margin, all found the presence of FoxP3 to be as-
sociated with better survival, regardless of tumour compartment as-
sessed [71,83,98]. Four studies performed a combined assessment of
FoxP3 at the invasive margin and intratumoural [59,71,118,126], of
which 2 found a significant positive association with survival [71,118].
Eleven studies (3822 patients) used an electronic method of assessment
[54,59,60,82,83,90,92,117–120], of which eight (3336 patients) found
a significant association of FoxP3 with better survival
[54,60,83,90,92,117–119]. Eleven studies (2789 patients) used a
manual method of assessment [71,74,84,98,110,112,115,126,130,
132,133], of which five (2267 patients) found a significant effect of
FoxP3 on survival [71,98,130,132,133], one of which was both positive
and negative [130]. Eight studies assessed the presence of MSI: of
which one found FoxP3 to be independent of MSI [71]; two found MSI
not to be independently significant for survival [74,117]; one study
assessed FoxP3 in MSI and MSS subgroups separately and found FoxP3
to be significant in the MSS subgroup [132]; two groups did not include
MSI in multivariate analysis [54,112]; and two groups found that FoxP3
was not independent of MSI for survival [83,92]. Fifteen independent
studies (4040 patients) used an arbitrary data cut-off
[54,71,74,84,90,98,110,112,115,117–120,130,133], of which nine
studies (3357 patients) found a significant association with survival
[54,71,90,98,117–119,130,133]. Five studies (2434 patients) used a
data-driven cut-off [60,82,83,92,132], four (2246 patients) of which
were associated with better survival [60,83,92,132]. For two studies
(137 patients), the data cut-off method was unclear [59,126].
Five studies met inclusion criteria for meta-analysis of IT FoxP3 in
colorectal cancer (Table 4, Fig. 10C): two assessed DFS (HR 0.52; 95%
CI: 0.36–0.77), with no significant heterogeneity; four assessed OS (HR
0.72; 95% CI: 0.65–0.80), with substantial heterogeneity (I2 77%;
p= 0.004); and three assessed DSS (HR 0.47; 95% CI: 0.37–0.61), with
no significant heterogeneity. Funnel plot appeared to be skewed to the
left indicating a bias against smaller studies with no significant differ-
ence in survival outcome. Three studies were included for IM FoxP3
(Table 4, Fig. 10D): one assessed DFS finding a significant survival
benefit; two assessed OS (HR 0.47; 95% CI: 0.35–0.63), with no sig-
nificant heterogeneity; and three assessed DSS (HR 0.57; 95% CI:
0.46–0.70), with substantial heterogeneity (I2 63%; p = 0.07). Funnel
plot contained too few studies to comment on publication bias.
Immunoscore
The Immunoscore is a patented score and a trademark of Inserm
developed by Galon and colleagues over the last two decades
[6,63,64,109,146,147]. The score involves an electronic assessment of
the presence of two T-cell markers in the tumour centre (IE + ST) and
at the IM giving 4 parameters, dichotomised in each region and for each
cell type with a ROC curve into high or low. One point is assigned to
each parameter scoring “high” and these points are added together to
give a maximum score of 4 and a minimum of 0 [109]. The original
score used CD3 and CD45RO [63] as the two immune markers. Over
time this evolved to use a combination of CD45RO and CD8 [109,147],
but was subsequently modified again to use CD3 and CD8 [6,64]. This
latter combination has been validated in a large international con-
sortium with 2681 patients [6]. The score can be performed on either
TMA [63,64,109,147] or whole sections [6,148]. This work has been
replicated by other groups: some using the same software [149], others
using alternative electronic cell counting software [12,62,99,150], and
others performing a manual assessment using the immunoscore method
[98,151]. Still others have adapted the score with additional items in
the case of stage IV disease such as the addition of a Granzyme B marker
(an additional marker of cytotoxic T-cell activation) [152], assessment
of CD3 and CD8 in the tumour metastasis as well as the primary
[153,154] or addition of CD163 (an M2 macrophage marker) [153],
since stage IV disease is not effectively stratified by the immunoscore
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alone [63]. In total, fourteen studies assessed a version of the Im-
munoscore in rectal, colon or colorectal cancer, although three studies
had overlapping populations [64,109,151], leaving eleven independent
studies comprising 4624 patients [6,12,62,98,99,147,149,150,
152–154], of which only one (60 patients with stage IV disease) found
no significant association with survival [154].
In rectal cancer, one study (83 patients) assessed the Immunoscore,
which was significant for survival [64]. They used an electronic
method, counting CD3 and CD8 stained cells, and a data-driven cut-off.
MSI was not assessed and they used the original 5 group split [64]. This
study did not meet inclusion criteria for meta-analysis.
There were two studies (2827 patients) in colon cancer [6,12], both
of which were significant for better survival. Both studies assessed
primary colon cancer, although there were issues in one study with
scoring CD8 in the tumour centre, leaving a total score of 3 [12]. Both
studies used an electronic method of assessment, although one used the
patented software [6] and the other used freeware [12]. Both studies
assessed the presence of MSI: one found Immunoscore to be in-
dependent of MSI [6]; the other was unclear since they used a forward
stepwise model [12]. One study used an arbitrary cut-off [6], whilst one
used a data-driven cut-off [12].
One study met inclusion criteria for meta-analysis (Table 3) for
immunoscore in colon cancer and this was significant for DFS and OS.
In colorectal cancer, two groups used overlapping cohorts
[109,151], leaving nine independent studies comprising 1797 patients
[62,98,99,147,149,150,152–154]. Only one of these studies was not
significant for survival and this was a small study of 60 patients with
stage IV disease [154]. There were four studies assessing the efficacy of
Fig. 11. Forest plot and funnel plot for Immunoscore in colorectal cancer according to DFS, OS and DSS.
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the Immunoscore in metastatic disease, all of whom adapted the im-
munoscore to suit: two groups assessed the immunoscore only on liver
metastases [62,152], one of whom added Granzyme B as a third marker
in addition to CD3 and CD8 [152]; the other two assessed the im-
munoscore in the primary tumour centre, invasive margin and in the
metastasis [153,154]; one of these also added in assessment of CD163
(as an M2 macrophage marker) in the primary in addition to the im-
munoscore [153]. Eight used an electronic method of assessment
[62,99,147,149,150,152–154], although two of these used freeware
[62,150]. One group used a manual method of assessment [98]. Three
groups assessed the presence of MSI: of which one found Immunoscore
to be independent of MSI [149]; one found that MSI was not significant
for survival [151]; and one had only MSS tumours [152]. Three studies
employed an arbitrary data cut-off method [62,98,150]. Five studies
employed a data-driven cut-off, including the study that did not find a
significant difference [99,147,149,153,154]. One study’s data cut-off
method was unclear [152]. Three groups used the originally proposed
5-category method of splitting cases [98,147,149]; whereas the re-
maining six dichotomised the data to give a high vs low score
[62,99,150,152–154]).
Five studies met inclusion criteria for meta-analysis for
Immunoscore in colorectal cancer (Table 4, Fig. 11): three assessed DFS
(HR 0.49; 95% CI: 0.41–0.58), with considerable heterogeneity (I2 91%;
p < 0.001); three assessed OS (HR 0.61; 95% CI: 0.53–0.70), with
considerable heterogeneity (I2 89%; p < 0.001); and five assessed DSS
(HR 0.47; 95% CI: 0.39–0.55), with considerable heterogeneity (I2 86%;
p < 0.001). Funnel plot assessment was performed which showed that
publications were significantly skewed to the left, with no studies
showing no significant difference and the plot itself was wide indicating
large variations in results. One study in particular was identified as an
outlier [109].
CD20 (B-cell marker)
CD20 is a generic B-cell marker, whose role in anti-tumour patho-
physiology is to interact with T-cells in co-ordinating the host defence
by producing various cytokines and chemokines in order to recruit and
activate T-cells, in addition to acting as antigen presenting cells
[155,156]. Furthermore, mature B-cells produce antibodies directed
against foreign entities [155,156]. They tend to form tertiary lymphoid
structures or lymphoid aggregates in colorectal cancer [41], but are also
found infiltrating the tumour itself [89,91].
There were six independent studies (1491 patients) staining for
CD20 in colorectal cancer [60,89,91,157–159], of which five (1374
patients) found it to be significant for better survival [60,91,157–159].
Four papers assessed CD20 in the intratumoural compartments
[60,89,91,159], of which three found a significant association with
survival [60,91,159]. Two papers assessed CD20 at the invasive margin
[89,158], of which only one was significant for survival [158]. One
study assessed CD20 on the whole slide (intratumoural as well as at the
invasive margin) and this was significant for better survival [157].
There were no studies with significant findings comparing more than
one tumour compartment. Four studies used an electronic method of
assessment, all of which were significant for survival [60,91,157,158].
Two studies used a manual method of assessment [89,159], of which
one was significant for survival [159]. Only one study assessed the
presence of MSI but did not include it in multivariate analysis [159].
Two studies used an arbitrary data cut-off [89,91], of which one was
significant for survival [91]. Three used a data-driven cut-off, all of
which were significant for survival [60,157,159]. The data cut-off was
unclear in one study [158].
Three studies met inclusion criteria for meta-analysis for IT CD20 in
colorectal cancer (Table 4, Fig. 12): one assessed DFS finding it to be
Fig. 12. Forest plot and funnel plot for IT CD20 in colorectal cancer according to DFS and OS.
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significant for survival; two assessed OS (HR 0.66; 95% CI: 0.52–0.89),
with no significant heterogeneity. Funnel plot provided no meaningful
data regarding publication bias.
CD56/CD57 (natural killer cells)
CD56 and CD57 are cell surface markers commonly expressed on
the surface of natural killer (NK) cells [160–162], whose role as part of
the innate immune system is to induce cell lysis although they may also
have an immunoregulatory role [163]. CD56 is a more generic NK cell
marker and can potentially also be expressed on other immune cells
[160], whereas CD57 is a mature NK cell marker and is suggestive of
terminal differentiation [162].
One study (149 patients) assessed natural killer cells in rectal
cancer, finding increased density to be associated with survival in the
post-resection specimen [164]. They measured intratumoural CD56
using an electronic method and an arbitrary data cut-off. MSI was not
assessed. This study met inclusion criteria for meta-analysis (Table 5)
and was significant for OS.
There were five studies (634 patients) in colorectal cancer
[9,29,30,165,166], of which four (502 patients) were significant for
better survival [9,29,165,166]. All five studies assessed the in-
tratumoural compartments, of which three found intratumoural natural
killer cells to be significant for survival [29,165,166]. Two studies as-
sessed natural killer cells at the invasive margin [9,30], one of which
found a significant effect on survival [9]. Only one paper with sig-
nificant findings assessed natural killer cells in more than one tumour
compartment, finding that their presence at the invasive margin was
significant for survival, whereas their presence within the tumour was
not [9]. However, three other studies assessing intratumoural natural
killer cells found their presence to be significant for better survival
[29,165,166]. All the studies in natural killer cells in colorectal cancer
used a manual method of assessment. Only one study assessed the
presence of MSI but did not include it in multivariate analysis [9]. Two
studies used an arbitrary data cut-off, both of which were significant for
survival [9,29]. One study used a data-driven cut-off, and this was
significant for survival [165]. The cut-off was unclear for the remaining
two studies [30,166]. When broken down by antibody markers, neither
of the papers assessing CD56 in colorectal cancer found any significant
difference in survival [9,30], although the study in rectal cancer found
the presence of CD56 positive cells to be associated with better survival
[164]. All the papers assessing CD57 were significant for survival
[9,29,166]. The only paper comparing CD56 and CD57 staining in
colorectal cancer found CD57 to be significant for better survival,
where CD56 was not [9]. One group stained for intratumoural Va24, a
marker of activated natural killer T-cells, which was also asso-ciated
with better survival [165].
Two studies met inclusion criteria for meta-analysis of IT CD56/57
in colorectal cancer (Table 4, Fig. 13): both assessed DFS (HR 0.47; 95%
CI: 0.28–0.78), with substantial heterogeneity (I2 71%; p = 0.06); both
also assessed OS (HR 0.48; 95% CI: 0.28–0.84), with no significant
heterogeneity. Funnel plot did not add meaningful data regarding
publication bias since numbers were too few. No studies met inclusion
criteria for meta-analysis of IM CD56/57.
Macrophages
Part of the innate immune response, macrophages play a main role
in phagocytosis and antigen presentation. They have been implicated in
anti-tumour defence and T-cell recruitment [167], but have also been
implicated in a pro-tumour role [168] and have been shown to the
express immune checkpoint protein PDL1 [169], believed to play a role
Fig. 13. Forest plot and funnel plot for IT CD56/57 in colorectal cancer according to DFS and OS.
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in immune resistance [170]. CD68 is a generic macrophage marker,
whereas CD163 and CD206 are believed to be markers more specific to
M2 tumour associated macrophages that have been associated with a
worse outcome [171]. There were twenty-two studies overall in colon
or colorectal cancer although one study had an overlapping population
[172], leaving twenty-one independent studies comprising 4879 pa-
tients [60,83,85,87,89,91,96,111,122,123,168,171,173–181]. Of these,
eleven studies (2038 patients) found that higher infiltration of macro-
phages were associated with a better prognosis
[60,83,87,96,122,175–178,180,181], compared with five studies (1965
patients) finding a worse prognosis [85,168,171,173,179].
In colon cancer, two studies (1070 patients) assessed macrophage
markers and survival. One study of 835 patients assessed CD68 and
CD206 [171]. CD68 assessment in the intratumoural stromal com-
partment was not associated with survival, whereas CD206 was asso-
ciated with worse survival [171]. The other paper assessed CD163 in
the intratumoural stromal compartment, which was associated with
worse survival [173]. One used an electronic assessment method and a
data-driven cut-off [171], whereas the other used a manual method and
an arbitrary cut-off [173]. Neither paper assessed the invasive margin.
Both assessed the presence of MSI: one found that MSI was not sig-
nificant for survival [171]; the other did not include MSI in survival
analysis [173]. Neither study met inclusion criteria for meta-analysis.
Sixteen independent studies (3528 patients) assessed CD68 in col-
orectal cancer: of which ten (1998 patients) were associated with an
improved outcome [60,83,87,96,122,175,177,178,180,181], one (654
patients) was associated with a worse outcome [85] and five (876 pa-
tients) found no difference [89,91,111,123,174]. The study that found a
negative impact of CD68 on survival measured it in the IE compartment
and ST compartment, finding that the presence of CD68 in the IE
compartment impacted negatively on survival, whereas CD68 in the ST
compartment made no difference to survival [85]. However, another
three studies also measured CD68 in the IE compartment: of which two
studies (187 patients) found no difference to survival [87,89]; while
one (201 patients) found it to be associated with improved survival
[178]. Twelve studies in total assessed intratumoural CD68
[60,83,85,87,89,91,96,111,122,174,175,177,178], of which five (796
patients) found it to be associated with better survival
[60,96,122,175,178], whereas one found it to be associated with worse
survival as already mentioned [85]. Eight studies assessed CD68 at the
Fig. 14. Forest plots and funnel plots for macrophage markers in colorectal cancer according to DFS, OS and DSS: (A) IT CD68; (B) IM CD68; (C) IM CD163.
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invasive margin: of which five found it to be associated with better
survival [83,87,177,180,181], compared with 3 that identified no as-
sociation [89,111,123]. Of the three studies that assessed CD68 both
intratumoural and at the invasive margin, all found the invasive margin
to be significantly associated with better survival, whereas in-
tratumoural measurement was not significant [83,87,177]. Five studies
used an electronic method of assessment [60,83,85,91,111], of which
two found CD68 to be associated with better survival [60,83] and one
with worse survival [85]. Eleven studies used a manual assessment
method [87,89,96,122,123,174,175,177,178,180,181], of which only
three found no association with better survival [89,91,123]. Four stu-
dies assessed the presence of MSI: of which one found CD68 to be as-
sociated with better survival, independent of MSI [181]; one found that
CD68 was not independent of MSI [83]; while two did not include MSI
in multivariate analysis [85,178]. Eleven studies used an arbitrary data
cut-off [85,96,111,122,123,174,175,177,178,180,181], of which only
three found no impact on survival [111,123,174]. Two studies used a
data-driven cut-off, both of which found a significant association of
CD68 with survival [60,83]. The cut-off method was unclear for the
other three studies [87,89,91].
Six studies met inclusion criteria for meta-analysis of IT CD68 in
colorectal cancer (Table 4, Fig. 14A): three assessed DFS (HR 1.21; 95%
CI: 0.95–1.55), with substantial heterogeneity (I2 81%; p= 0.005); five
assessed OS (HR 0.91; 95% CI: 0.75–1.11), with substantial hetero-
geneity (I2 77%; p = 0.002); and two assessed DSS (HR 0.58; 95% CI:
0.38–0.89), with no significant heterogeneity. The funnel plot revealed
most results to be grouped towards a positive influence of CD68 on
survival, apart from a single large study indicating a negative effect on
survival [85], which skews data to the right. Three studies were in-
cluded for IM CD68 (Table 4, Fig. 14B): one assessed DFS, with a sig-
nificant positive effect on survival; three assessed OS (HR 0.48; 95% CI:
0.36–0.64), with moderate heterogeneity (I2 48%; p = 0.15); and one
assessed DSS with significant positive survival impact.
Six studies (1540 patients) assessed CD163 in colorectal cancer, of
which two (508 patients) found it to be associated with an improved
survival outcome [172,176], two (241 patients) were associated with a
worse outcome [168,179], and two found no association with survival
[85,178]. Four studies assess intratumoural CD163 [85,176,178,179],
of which one found it to be associated with better survival [176] and
one found it to be associated with worse survival [179], while the other
two studies found no significant difference in survival outcomes. Two
studies assessed IM CD163, of which one was associated with worse
survival [168], while the other was associated with better survival
[172]. There were no studies that compared CD163 at the invasive
margin versus intratumoural. Two studies used an electronic assess-
ment method: one was associated with worse survival [179] and one
was not associated with survival [85]. Four studies used a manual as-
sessment [168,172,176,178], of which two were associated with better
survival [172,176], while one was associated with worse survival
[168]. Three studies assessed the presence of MSI, but none of them
included this in survival analysis [85,172,178]. All six studies used an
arbitrary cut-off apart from one that used a data driven cut-off [179].
No studies on IT CD163/206 met inclusion criteria for meta-ana-
lysis. Two studies for IM CD163 were included in meta-analysis for
colorectal cancer (Table 4, Fig. 14C): one assessed DFS finding a sig-
nificantly worse survival outcome; the other assessed DSS, with no
significant survival difference, but a trend towards better survival.
Two studies compared CD68 and CD163 stained cells [85,178].
Both found CD68 to be significant for survival, where CD163 was not.
However, one (654 patients) found CD68 was associated with worse
survival [85], but the other (201 patients) better [178]. A further group
studied the same population (468 patients) in two separate studies, one
looking at CD68 [180] and the other at CD163 [172], but they found
that both markers were associated with better survival.
Discussion
The complex nature of the interaction between the tumour and host
immune system has long been investigated. It is clear from the large
body of evidence displayed that a strong local inflammatory response is
a positive prognostic indicator. Conversely, lack of a co-ordinated local
inflammatory response results in a poor outcome. This issue is some-
what confounded by the presence or absence of MSI and it is remark-
able how few studies have taken MSI into account in survival analysis.
The main aim of this review was to present evidence for survival
outcomes based on assessment of the local inflammatory response in
colorectal cancer. As a result, a secondary aim was to determine whe-
ther any particular inflammatory assessment had superior prognostic
value, enabling a step towards incorporating assessment of the immune
microenvironment in colorectal cancer into clinical practice.
In the past, some have advocated that not only the density of the
local inflammatory response, but also the subtype of cells present and
the location of these cells within the tumour microenvironment hold
equal prognostic information [63,96,182]. However, in terms of cell
type, the results of the meta-analysis presented show similar fixed ef-
fects summaries regardless of cell type assessed, with the exception of
FoxP3 and macrophages. Furthermore, the fixed effects summaries are
similar regardless of whether an H&E assessment method or IHC for a
specific cell subtype is employed.
In terms of location of inflammatory cells, combined effects models
were similar regardless of whether intratumoural assessment or as-
sessment at the invasive margin were performed. In addition, those
studies that compared IT assessment with IM did not agree on whether
the presence of inflammatory cells in one compartment conveyed su-
perior survival advantage over the other.
When considering FoxP3 regulatory T-cells and macrophages, even
these cell subtypes are associated with improved survival on the whole,
but there does appear to be more heterogeneity in the literature re-
garding their positive or negative influence on survival outcomes. The
negative impact of FoxP3 on survival has been attributed to the reg-
ulatory nature of this T-cell subset in dampening the effects of cytotoxic
T-lymphocytes [144]. In the case of macrophages, the negative prog-
nostic effect has been attributed to the protumour effects of the “M2
macrophage” phenotype [168,183]. Both of these immune cell subsets
may therefore be implicated in the immunoediting that tumours are
believed to perform as they develop and evade or escape the host im-
munosurveillance [184].
The fact that most, if not all of the inflammatory cells assessed
contribute to an improved survival outcome indicates that it is the
density of a healthy, functional and co-ordinated immune response of
all cell types that drive an effective anti-tumour response [45,98].
Conversely, it might be said that no cell type acting in isolation could
effectively oppose tumour growth and metastasis. Hence those tumours
with higher densities of infiltrating immune cells are associated with
earlier stage, both in terms of depth of invasion and lymphatic and
haematogenous spread [98,182].
However, the question remains as to which method of assessing
peritumoural inflammatory response is optimal in colorectal cancer. If
concordance could be achieved regarding a universal assessment
method, then an inflammatory assessment could be incorporated into
the colorectal cancer dataset to compliment TNM staging and other
clinicopathological variables and guide the most appropriate post-
operative management for each patient. This issue is especially im-
portant given the increasing use of immunotherapies in identifying
which patients would derive greatest benefit.
The most studied immune cell subtypes and therefore those with the
greatest combined evidence behind their use are CD8, CD3 and FoxP3.
FoxP3, given the heterogeneity in terms of survival outcomes is less
ideal for a generalised marker of the anti-tumour immune response. Not
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only have the utilities of CD3 and CD8 individually been shown for
colorectal cancer, both markers were associated with better prognosis
when present in colon cancer and rectal cancer. Furthermore, the pre-
sence of CD3 and CD8 in preoperative biopsies was associated with
better prognosis [69,76,103].
There is an argument for the use of a simple H&E based method like
the Klintrup-Makinen grade: it is a validated method with similar fixed
effects summaries to IHC methods; it is cost-effective, using routinely
assessed slides in clinical pathology with no requirement for special
stains. However, there are fewer studies reporting this method and
therefore the evidence is less robust and there is an element of inter-
observer variability in the published literature.
Similarly, CLR is able to stratify prognosis, but with even less
published literature than for KM and the range of methods that have
been used to assess CLR, in addition to the variability in cut-offs used
mean that the pooled evidence for CLR is weak. The same could also be
said for TILs counted on H&E, CD4, CD45RO, CD20, and CD56/57. All
of these assessments have an overall positive survival effect, but the
evidence was not strong.
Furthermore, if an IHC method was preferred, the next question
would be to agree a standardised assessment approach. There are those
who have advocated for digital pathology and the use of patented
software to achieve a standardised method with excellent reproduci-
bility [6]. However, the rationale for this approach hinges on the fact
that it matters which tumour compartment the inflammatory cells are
found in, but the published literature does not support this theory.
Furthermore, the incorporation of this method of assessment into rou-
tine clinical practice necessitates not only that all colorectal cancer
cases are assessed in pathology laboratories with digital pathology fa-
cilities, but also that the patented software is purchased on a global
scale. In addition, there is evidence of significant publication bias re-
garding the immunoscore, although the recent large prospective con-
sortium trial provides high quality evidence that it does stratify survival
[6].
There are a range of methods of quantifying the extent of infiltration
of CD3 and CD8, from semiquantitative scoring and manual counts to
digital image analysis and automated counting. Around half of the
studies included in meta-analysis for both CD3 and CD8 used a manual
assessment and this did not impair their ability to identify those with a
higher inflammatory infiltrate, which would suggest that an electronic
assessment is not essential to the implementation of an IHC-based
method of assessing host anti-tumour immune response in routine
clinical practice. The only study to directly compare manual and elec-
tronic assessment of IHC for CD3 found a good intraclass correlation co-
efficient between manual and automated cell counting [97].
MSI is a known confounding factor in colorectal cancer for any in-
flammatory assessment due to the greater inflammatory response that
these tumours stimulate, a feature that has been attributed to greater
quantities of neo-antigen generation [18]. Having said this, nearly half
of the included studies did not assess for the presence of MSI and even
less included this in multivariate analysis. However, in many studies
MSI was not found to influence survival and in those where it did, there
were several studies that showed that the survival benefit offered by a
strong anti-tumour immune response was independent of MSI.
In the same way as patients with MSI and stage II disease are un-
likely to require adjuvant therapy [19], those with a dense local in-
flammatory response would be offered similar protection.
Conclusion
Based on the weight of published evidence available, the authors
advocate a standardised approach to assessing the immune response to
colorectal cancer in routine clinical practice to further stratify survival
and dictate individualised management. However, whether this as-
sessment should be a simple validated H&E method alone, such as the
Klintrup-Makinen grade, or whether it should require IHC for immune
cell subtypes, or a combination of these methods, requires further as-
sessment. CD3 may act as a surrogate marker of overall T-cell infiltrate,
but the authors caution against undue focus on any individual cell type
at the expense of the overall inflammatory infiltrate, since it is likely to
be a co-ordinated immune response that provides the observed pro-
tective effect on survival.
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